Bio-Path (NASDAQ:BPTH) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Bio-Path (NASDAQ:BPTH) in a report released on Saturday morning. The firm issued a sell rating on the stock.

Bio-Path Price Performance

Shares of NASDAQ:BPTH opened at $0.81 on Friday. The firm has a 50 day moving average of $0.98 and a 200 day moving average of $1.58. Bio-Path has a 52 week low of $0.80 and a 52 week high of $12.40.

Bio-Path (NASDAQ:BPTH) last announced its earnings results on Thursday, August 15th. The company reported ($1.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.54) by $0.38. During the same period last year, the business earned ($10.60) EPS. Equities research analysts predict that Bio-Path will post -6.2 EPS for the current year.

Institutional Trading of Bio-Path

An institutional investor recently bought a new position in Bio-Path stock. Armistice Capital LLC purchased a new stake in Bio-Path Holdings, Inc. (NASDAQ:BPTH) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 97,000 shares of the company’s stock, valued at approximately $194,000. Armistice Capital LLC owned 4.66% of Bio-Path at the end of the most recent quarter. 5.74% of the stock is currently owned by institutional investors.

About Bio-Path

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.